Tekna Holding ASA announced on October 20, 2026 that its Materials business segment has received an order totaling C$1.6 million from a European distributor serving global medical device manufacturers. The order covers Ti64 (Ti-6Al-4V) titanium alloy powder in laser powder bed fusion (LPBF) particle size specifications and is included in the company's Q4 2026 order intake. The powder will be delivered in batches throughout 2027. The order builds on Tekna's recently renewed ISO 13485:2016 certification for medical device design and manufacturing quality management systems. CEO Claude Jean stated that medical is one of the fastest-growing additive manufacturing markets, with strong demand for high-quality powder for patient-specific devices and implants, and that this order also reflects the deepening of a long-standing distributor relationship. Medical implants represent a rigid-demand application for titanium alloy powder. The European distributor's order indicates steadily growing end-customer acceptance of plasma-atomized, spheroidized titanium powder for medical-grade LPBF applications. Tekna has previously received repeat orders from a U.S. defense customer, with medical and defense forming the two major growth pillars of its powder business. Value for powder buyers: (1) Medical-grade Ti64 powder is entering the stage of volume supply, and domestic powder suppliers can assess the ISO 13485 certification gap to evaluate medical market access; (2) The expansion of European medical distribution channels highlights that particle size distribution and oxygen content control are key competitive factors for titanium powder used in medical implants; (3) The 2027 delivery schedule provides a demand-side reference for powder capacity planning.